Drug intelligence / Profile preview

BGP-15

Development stage
Phase 2
Lead developer
N-Gene Research & Development
Modality
Small Molecules
Administration
Oral
01

Overview

BGP-15 is a small molecule drug developed as an insulin sensitizer and cellular protectant. It acts through multiple mechanisms, including inhibition of poly(ADP-ribose) polymerase (PARP), stimulation of heat shock protein 70 (HSP70), inhibition of Jun kinase (JNK) mitogen-activated protein kinase, and reduction of reactive oxygen species (ROS) production. BGP-15 has shown efficacy in improving insulin sensitivity in animal models and humans with insulin resistance, as well as protective effects in conditions such as Duchenne muscular dystrophy, diastolic dysfunction, tachycardia, heart failure, atrial fibrillation, chemotherapy-induced damage, reperfusion injury, and mitochondrial-stress-related diseases. The drug also exhibits chemoprotective properties during cytostatic therapies and photoprotective effects[1][5][4]. Its precise mechanism is multifactorial but centers on modulation of stress response pathways and cellular protection.

Other names
(+/-)-o-(3-piperidino-2-hydroxy-1-propyl)nicotinic acid amidoxime3-pyridinecarboximidamide n-(2-hydroxy-3-(1-piperidinyl)propoxy)bgp-15 free basebgp15 free basebgp 15 free base
02

Targets

HSP70 (Heat shock protein 70)JNK (Mitogen-activated protein kinase kinase kinase family)PARP1 (Poly (adp-ribose) polymerase 1)

Beyond the preview

Go deeper on BGP-15.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on BGP-15.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call